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Abstract
Purpose—To review our clinical experience and determine if there are appropriate signs and
symptoms to consider POLG sequencing prior to valproic acid (VPA) dosing in patients with
seizures.
Methods—Four patients who developed VPA-induced hepatotoxicity were examined for POLG
sequence variations. A subsequent chart review was used to describe clinical course prior to and
after VPA dosing.
Results—Four patients of multiple different ethnicities, age 3–18 years, developed VPA-induced
hepatotoxicity. All were given VPA due to intrac partial seizures. Three of the patients had
developed epilepsia partialis continua. The time from VPA exposure to liver failure was between 2
and 3 months. Liver failure was reversible in one patient. Molecular studies revealed homozygous
p.R597W or p.A467T mutations in two patients. The other two patients showed compound
heterozygous mutations, p.A467T/p.Q68X and p.L83P/p.G888S. Clinical findings and POLG
mutations were diagnostic of Alpers–Huttenlocher syndrome.
Conclusion—Our cases underscore several important findings: POLG mutations have been
observed in every ethnic group studied to date; early predominance of epileptiform discharges
over the occipital region is common in POLG-induced epilepsy; the EEG and MRI findings
varying between patients and stages of the disease; and VPA dosing at any stage of Alpers–
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Huttenlocher syndrome can precipitate liver failure. Our data support an emerging proposal that
POLG gene testing should be considered in any child or adolescent who presents or develops
intractable seizures with or without status epilepticus or epilepsia partialis continua, particularly
when there is a history of psychomotor regression.
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1. Introduction
Alpers1 described the syndrome that bears his name; refractory seizures, developmental
regression, cortical blindness, and age of onset 3–7 years. The liver findings were
subsequently noted by Huttenlocher et al.2 However, it was not until Bicknese et al.3
described valproic acid (VPA) toxicity in six children with Huttenlocher variant of Alpers
syndrome that VPA-induced liver toxicity and Alpers syndrome were connected [Alpers–
Huttenlocher syndrome is synonymous with Alpers syndrome]. Subsequently, Naviaux and
Nguyen4 made the discovery that mutations within the mitochondrial DNA replicase,
polymerase gamma 1 (POLG) was responsible for Alpers–Huttenlocher syndrome.
Although now, POLG mutations, Alpers–Huttenlocher syndrome, and VPA-induced liver
failure are known, there remains the question on how to predict patient populations where
VPA exposure should be avoided.
The mechanism of POLG with VPA-induced liver failure is not clear. POLG together with
deoxyguanosine kinase and MPV17, are the nuclear genes responsible for most cases of the
hepatocerebral (OMIM 251880) form of mitochondrial DNA (mtDNA) depletion.5–7 Only
the mutations in POLG and the mitochondrial DNA helicase TWINKLE have been
associated with genetically proven VPA-induced liver failure.8 Human POLG is a
heterotrimer, composed of one p140 catalytic subunit encoded by the POLG gene and two
p55 accessory subunits encoded by the POLG2 gene.9,10 More than 150 pathogenic POLG
mutations have been reported in patients with a broad spectrum of clinical phenotypes
(http://tools.niehs.nih.gov/polg/).
In this study, we describe the finding of four cases including infant, child, adolescent, and
young adult from different ethnic backgrounds who developed liver failure in response to
VPA dosing. Regardless of the age of onset of seizures, administration of VPA precipitated
liver failure within 2–3 months. Due to our increased understanding of this syndrome, we
tested two other children for possible POLG mutations prior to exposure to VPA and they
are still alive.
2. Methods
2.1. Patients and DNA
Blood samples of patients with clinical presentations suggestive of POLG deficiency were
evaluated at the Mitochondrial Diagnostics Laboratory at Baylor College of Medicine. Total
(nuclear and mitochondrial) DNA was extracted from peripheral blood leukocytes using
commercially available DNA isolation kits (Gentra Systems Inc., Minneapolis, MN),
according to the manufacturer’s protocols.
2.2. Sequencing analysis
Sequence-specific oligonucleotide primers linked to M13 universal primer sequences were
designed to amplify the 22 coding exons and at least 50 nucleotides of each flanking intron
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of POLG gene. PCR products generated using Fast Start DNA polymerase (Roche,
Indianapolis, IN) were purified on ExcelaPure 96-well UF PCR purification plates (Edge
BioSystems, Gaithersburg, MD). Sequencing reactions were performed using the BigDye
Terminator Cycle Sequencing kit (Version 3.1) and analyzed on an ABI3730XL automated
DNA sequencer with Sequencing Analysis Software v5.1.1 (Applied Biosystems, Foster
City, CA, USA). DNA sequences were analyzed using Mutation Surveyor Version 2.6.1 and
the GenBank POLG sequence; ID NM_002693.1.
2.3. Clinical reports
2.3.1. Patient 1—This patient is an 18-year-old Hispanic male, who displayed normal
development until 14 years of age when he was diagnosed with pulmonary tuberculosis
(Table 1). He had a full recovery. His first seizures were complex partial seizures also
occurred at 14 years of age. He failed antiepileptic therapy with oxcarbazepine and he was
placed on VPA. In 2 months, he had bilateral foot drop, pes cavus, and mild
ophthalmoplegia without obvious cognitive abnormality. Electromyography (EMG) testing
demonstrated a peripheral neuropathy. Within 24 h of muscle biopsy he developed
pancreatitis that progressed to multiple organ failure including kidneys, liver, lung, and
pancreas. VPA was stopped. The muscle biopsy showed fiber size variation, ragged red
fibers, and COX-negative fibers. Electron microscopy showed abnormal mitochondrial
ultrastructure with increased lipid droplets. Although VPA was stopped, his liver function
impairment progressed. Despite aggressive supportive care, he unfortunately died of sepsis
and adult respiratory distress syndrome 27 days after the biopsy.
2.3.2. Patient 2—POLG mutations and brief symptoms list have been briefly described.11
Previously healthy until 10-years of age the patient developed drop attacks suggestive of
ataxia or myoclonic seizures with electroencephalogram (EEG) showed photic convulsive
responses and infrequent generalized discharges during slow wave sleep (Table 1). She was
found to have a mild sensorineural hearing loss. At 15 years of age, she developed epilepsia
partialis continua (EPC). EEG demonstrated right occipital epileptiform discharges. EMG
examination demonstrated a moderate to severe symmetric sensory and motor axonal
peripheral neuropathy of lower extremities. A brain MRI showed multiple hyperintense T2/
FLAIR (fluid attenuated inversion recovery) changes in the right inferior frontal lobe, left
medial frontal lobe, left thalamus, bilateral parietal, and occipital lobes with the most
prominent lesion being the right occipital lobe. Repeated MRI 1 month later showed
resolution of these changes. Muscle biopsy showed fiber type 2 predominance (60%), and
scattered COX-negative fibers (6%). Electron transport chain (ETC) enzyme testing showed
<15% of normal activity in complex III. Muscle and lymphocyte mtDNA was negative for
common mitochondrial DNA mutations. Lamotrigine was started and she became seizure
free and EEG normalized. She did extremely well clinically until age 21, when she
developed increasing bouts of myoclonus. Initially, the myoclonus responded to
levetiracetam but after several months myoclonus became more severe and VPA was added.
Within 2 months she developed cognitive slowing, VPA was stopped, and she was
hospitalized for increasing encephalopathy and myoclonus. At admission, she was found to
be in liver failure. EEG demonstrated generalized slowing without epileptiform discharges.
MRI of the brain was normal. One month after VPA was stopped, liver transplant was
performed. Following transplant her liver function normalized but she developed periodic
lateralized epileptiform discharges on EEG. Mechanical ventilation could not be weaned due
to pulmonary edema and a right pneumothorax. Life support was withdrawn. She died
within 2 days of transplant. Liver biopsy of her pre-transplanted liver showed extensive
necrosis, bile stasis, bile ductular proliferation, moderate lymphoplasmacytic infiltration,
and bridging fibrosis on Masson trichrome stain. The transplanted liver was normal at
autopsy.
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2.3.3. Patient 3—The patient was initially brought to medical attention due to frequent
vomiting (projectile) episodes beginning during infancy. POLG mutations and brief
symptom summary have been previously reported.11 The mother had Crohn’s disease and
the father’s family had multiple members with Celiac and thyroid disease (autoimmune). At
18 months of age, she developed myoclonic jerks and was noted to be mildly ataxic with
developmental delay (Table 1). An EEG was performed and demonstrated occipital
epileptiform discharges. Due to formula intolerance and family history, at 33 months of age
she was evaluated for possible Celiac disease. She had elevated endomysial IgA and
transglutamase IgA titers and persistent eosinophilia. On small bowel biopsy, she showed
features consistent with but not diagnostic of Celiac disease. MRI scan showed two foci of
hyperintense T2/FLAIR lesions in the medial aspect of the left cerebellar hemisphere. MRI
gradient echo sequences did not detect calcifications. A gluten free diet had no effect on
formula tolerance, seizures or ataxia. Subsequently, she developed EPC with left hand clonic
movements and eye deviation to the left with visual hallucination of seeing spiders. EPC
was effectively treated with lorazepam, fosphenytoin, and phenobarbital. She developed
myoclonus. The EEG during this time continued to show occipital epileptiform discharges
(Fig. 1a and b). The posterior dominant rhythm was slow. Seizures continued, and VPA was
started at age 3 years. Due to increasing obtundation and seizures, she was admitted to the
hospital 3 months after starting VPA. On admission, liver failure was noted. VPA was
stopped. MRI was repeated showing increased T2/FLAIR signal in the periventricular white
matter, bilateral caudate, and thalami. The previous cerebellar lesions had resolved. The
child’s parents decided to take her home on hospice and she expired within 3 weeks.
2.3.4. Patient 4—This 10-year-old Chinese girl had unremarkable growth and
development except a mild elevation of hearing threshold, detected at 5 years of age. This
patient has been previously described.12 Briefly, seizures started at 9 years of age and were
multifocal partial seizures that often progressed to status epilepticus. EEG showed frequent
epileptiform discharges over central, parietal, and occipital regions with slowing of the
background (Table 1). Repeated EEG 7 months later demonstrated generalized slowing,
periodic slow and spike wave over the left hemisphere, and almost continuous spike and
wave discharges over the bi-occipital regions. Due to intractability to multiple medications,
VPA was started. VPA was stopped after 2.5 months due to liver failure. Since the initial
report,12 her liver function gradually improved and now has returned to near normal
functioning. Clinically, she has demonstrated development regression, losing the ability to
walk, sit, or speak and eventually progressed to a vegetative state. She remained in a
vegetative state until death at age 13.
2.3.5. Patient 5—Patient 5 (Table 2) did not receive VPA and will be discussed later. The
11-year-old boy was normal developing until 2.5 years, when he developed gait ataxia with
repeated episodes of ketotic hypoglycemia in the context of cyclic vomiting, requiring
multiple hospitalizations. He developed seizures at 6-years of age and seizures have been
intractable to antiseizure medications. An EEG at 10 years of age demonstrated generalized
epileptiform discharges suggesting generalized epilepsy (Fig. 2). Muscle biopsy was
performed for a suspicion of mitochondrial disease. ETC results were normal and
histochemical studies of the muscle demonstrated scattered COX-negative fibers. POLG
sequencing demonstrated compound heterozygous mutations, p.A467T and p.G848S.
Currently at 11-years of age, he has severe gastrointenstinal dysmotility, intractable
generalized seizures, ophthalmoplegia, myoclonus, bilateral eyelid ptosis, axial hypotonia,
muscle weakness and fatigue, and cognitive regression. He has just begun to develop signs
and symptoms of liver failure.
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2.3.6. Patient 6—Patient 6 (Table 2) did not receive VPA and will be discussed later. The
4-year-old girl began having seizures at the age of 2 years, with EPC arising from the right
occipital head region. The seizures were described as eye jerking/nystagmus to the left and
right. Seizures were treated with levetiracetam and oxcarbazepine. She became seizure free
after several days of combination therapy, However, there remained frequent spike and
wave discharges in the right occipital region on EEG. Otherwise her development has been
on tract. On neurological examination there is a mild wide-based gait with truncal ataxia.
She also has an intention tremor. The MRI of the brain was normal. POLG sequencing
detected heterozygous mutations p.G848S and p.W748S mutations.
3. Results
Only one (patient 2) of the four patients (with liver failure) described above was suspected
of having a mitochondrial disorder at the time of VPA dosing. She had a deficiency of
complex III noted on electron transport chain analysis. All patients were on polytherapy for
seizure control. The entire mitochondrial genome of patient 1 was sequenced but deleterious
mutations were not found. None of the patients were thought to have Alpers–Huttenlocher
syndrome. The sentinel finding of VPA-induced liver failure triggered mutational analysis
of POLG in patients 1–4.
Gene sequencing revealed a missense variant, c.1789C>T (p.R597W), in patient 1. In patient
2, a common homozygous POLG mutation, c.1399G>A (p.A467T), was detected. Patient 3
was compound heterozygous for a missense mutation, c.1399G>A (p.A467T) and a
nonsense mutation, c.202C>T (p.Q68X). Patient 4 was compound heterozygous for two
missense variants, c.248T>C (p.L83P) and c.2662G>A (p.G888S).
All patients had confirmed pathogenic mutations in POLG gene. Our four patients are of
diverse ethnic background and the age of disease onset varies from infants to adolescents to
young adults. Early growth and development appeared normal until the first seizures at 9
and 14 years of age for patients 4 and 1. Patient 2 had early ataxia with myoclonus and mild
sensorineural hearing loss. Myoclonus was essentially well controlled with lamotrigine. At
22-years of age, VPA was started. Although she was found to have a complex III defect, she
was homogygous for the p. A467T mutation and at autopsy had pathological findings of
liver and brain (data not presented) consistent with Alpers–Huttenlocher syndrome.
Complex IV defects have been found in Alpers–Huttenlocher patients13 and our patient 2
would suggest that complex III defects are also compatible with Alpers–Huttenlocher
syndrome. Patient 3 presented in infancy with projectile vomiting. Each patient developed
intractable complex partial seizures, with 3 patients developing EPC and/or status
epilepticus. In all patients VPA was administered for seizure control, ultimately leading to
liver failure and a genetic diagnosis. The time to liver failure was short in each,
approximately 3 months after VPA exposure. Patient 2 underwent an unsuccessful liver
transplant. Patients 1–3 died of acute problems from liver failure or transplant, while patient
4 eventually died from complications of liver failure.
4. Discussion
The incidence of fatal VPA-induced hepatotoxicity decreases with increasing age. In adults,
the incidence is about 1:40,000.14 In children under 2 years receiving polytherapy of VPA
with other antiepileptic medications, liver toxicity can be as high as 1/600.14 VPA is the
medication of choice for generalized seizure15,16 and efficacious in focal seizures as noted
in many studies and expert opinion articles.17–19 The efficacy of VPA in controlling both
generalized and focal seizures in the context of VPA-induced hepatic failure makes clinical
acumen of its use extremely important. Thinking that VPA-induced liver failure is an age-
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related disorder, many clinicians do not hesitate to use VPA in patients >2 years with
uncontrolled seizures. Furthermore, VPA is the medication of choice in another
mitochondrial disease syndrome, myoclonus, epilepsy with ragged red fibers (MERRF).20
Our data, together with the broad age range of patients with reported VPA-induced liver
failure with POLG mutations, suggests that VPA exposure is related to POLG genotype and
disease, in particular Alpers–Huttenocher syndrome.21–27
The onset of seizures may give clues to the presence of POLG mutations and Alpers–
Huttenlocher syndrome. Several reports have shown that patients with POLG mutations and
Alpers–Huttenlocher syndrome present with syndromic epilepsy with occipital lobe
predilection.5,21,23–25 In addition, our patient population (Table 1) and recent literature
demonstrates seizure semiology consistent with occipital lobe epileptic discharges; focal
clonic motor seizures, secondarily generalized tonic–clonic seizures, hallucinations and
nystagmus.23–25,28 However, early studies have not consistently shown occipital lobe
discharges, with some describing generalized discharges, hypsarrhythmia or multifocal
discharges.28,29 Tulinius and Hagne28 suggested that timing of the disease progression was
likely responsible for EEG variation. The predominance of reports with POLG proven
Alpers–Huttenlocher syndrome strongly suggests that the majority of patients presenting
with seizures have predominantly occipital lobe discharges. Often discharges are seen in the
context of EPC or status epilepticus.23–25 In one small study, five patients presented with
convulsive status epilepticus.21 Three of four of our patients would compliment focal EEG
findings within the occipital region and EPC in the course of their disease. However, not all
patients having Alpers–Huttenlocker have focal EEG patterns. Patients 2 and 5 had
generalized spikes, more reminisce of the report by Boyd et al.29 One of our patients (patient
2) demonstrated that normal EEG findings are also possible during the course of the
syndrome. We agree with Tulinius and Hagne28 that EEG may change during the course of
this disorder. Most patients, at the time of seizure onset will display a focal pattern with
posterior head distribution. Some may have generalized discharges, but this is likely
uncommon early, but may be seen later in the course of the disorder (patients 2 and 5). As
demonstrated in our patients, most, if not all, will have abnormal slowing of the background
frequency suggesting encephalopathy. However, the EEG may also be normal as seen in
patient 2.
In one study, epileptiform discharges were high amplitude delta frequency waves with
superimposed polyspikes.21 However, this was not the case in our population (Figs. 1 and
2). This would suggest that although the EEG is very helpful in location and frequency of
epileptiform discharges, discharges can be variable and clinical acumen is required
interpreting findings with diagnostic conclusions.
Three of our patients (patients 2–4) had EPC sometime in their disease, with another patient
(patient 4) having a status epilepticus event. Patient 1 did not have documented episodes of
either EPC or status epilepticus. The literature and our findings would suggest that most
patients with Alpers–Huttenlocher syndrome have explosive seizure onset, usually
presenting with occipital lobe semiologies and frequent bouts of EPC and/or status
epilepticus during the course of their disease. Patients with other mitochondrial diseases
such as Leigh syndrome, MELAS, mitochondrial transfer RNA mutations and electron
transport chain disorders have been associated with EPC.30–32 Therefore, careful evaluations
for other possible mitochondrial diseases33–35 and other etiologies of EPC need to be
investigated.
Most of the other patients with POLG mutations and VPA-induced liver toxicity were
reported from Caucasian of Northern European countries and had similar POLG
mutations.23–25 Our patients are of diverse ethnicities including Hispanic, Caucasian,
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northern European, and Chinese. This emphasizes that POLG mutations and VPA
hepatotoxicity can be pan-ethnic. Furthermore, VPA-induced hepatotoxicity can happen at
any age or stage of the disorder.
Screening of the five most common mutations, p.A467T, p.W748S, p.G848S, p.T914P, and
p.T251I + p.P587L in POLG gene would detect both mutant alleles in about half of cases
with recessive POLG-related disease and one mutant allele in about one third of cases.11
However, our experience and the literature22,36 suggests that other mutations exist and
therefore, screening for these most frequent mutations may not adequately screen for POLG-
related disorder in a particular patient. Therefore, full gene sequencing of POLG is currently
the most efficacious method to use before VPA dosing.
Review of the cases with POLG mutations and liver failure induced by VPA revealed that
most patients had unremarkable clinical history before seizure onset. Often the early clues to
a particular mitochondrial DNA depletion syndrome are elusive and therefore, more caution
is required. Any ethnicity should be suspected. Early development is likely to be normal.
The initial symptoms may be explosive seizures that have an occipital lobe predominance
and difficult to control with medications. Seizures may occur at any age during infancy
through adolescence. The EEG pattern will often be focal discharges from the occipital lobe
region and seizure semiology will be compatible with occipital lobe epilepsy. There likely
will be frequent bouts of EPC and status epilepticus. If there are MRI/MRS abnormalities
present, they will likely be represented by T2/FLAIR hyperintensity signals within the
thalamus, occipital region, and/or cerebellum (Table 1).21,28 MRS imaging may show the
presence of lactate peaks.21,33 Progressive psychomotor regression is almost universally
found when first symptoms appear. In this clinical scenario, POLG gene sequencing should
be performed. Using these principles, we have performed POLG gene sequencing prior to
VPA dosing based on clinical suspicion (Table 2). Patients 5 and 6 were found to harbor
compound heterozygous mutations described with Alpers–Huttenlocher syndrome. Both
patients are currently alive.
Currently, sequencing the POLG gene remains the best diagnostic test to prevent VPA-
induced liver failure and patient death. Although open to debate, it is our suggestion that
POLG gene testing should be standard before giving VPA for seizure treatment in this
genetic mitochondrial DNA depletion epilepsy syndrome. Our patients 5 and 6 are alive
because our clinical acumen induced our decision to sequence the POLG gene.
Abbreviations
POLG polymerase gamma
VPA valproic acid
MELAS mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like
episodes
MERRF myoclonus, epilepsy with ragged red fibers
MRI magnetic resonance imaging
MRS proton (1H) magnetic resonance spectroscopy
FLAIR fluid attenuated inversion recovery
MPV17 mitochondrial inner membrane protein
TWINKLE gene encoding mitochondrial helicase
PCR polymerase chain reaction
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Fig. 1.
This EEG epoch demonstrates occipital lobe epileptiform discharges of patient 3 at age 3
years. (a) Bipolar montage and predominant right occipital discharges. (b) Same epoch but
in a transverse montage. This view shows that the predominant discharge is right occipital.
The background rhythm is slow for age. Interestingly, in other EEGs, the occipital discharge
was predominantly left occipital.
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Fig. 2.
This EEG epoch shows generalized epileptiform discharges in a bipolar montage (patient 5).
This epoch demonstrates a large amplitude spike and wave discharge (large delta discharge
followed by a notched spike) at 2–2.5 Hz. There is also an intermittent slow that is maximal
bi-occipital with left occipital predominance. The background rhythm is slow for age.
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Table 1
Summary of clinical course of patients exposed to VPA.
Patient
1 2 3 4
Gender/age (years) Male/18 Female/23 Female/3.3 Female/10
Genotype allele 1/allele 2 c.1789C>T/c.1789C>T c.1399G>A/c.1399G>A c.1399G>A/c.202C>T c.T248C/c.G2662A
Amino acid change p.R597W/p.R597W p.A467T/p.A467T p.A467T/p.Q68X p.L83P/p.G888S
Ethnicity Hispanic Caucasian Caucasian Chinese
Health status before
seizure onset
Normal developmental and growth
status; pulmonary tuberculosis at 14-
years and recovery
Sensory neuropathy,
ataxia since 10 years
Celiac disease, mild
developmental delay,
ataxia
Mild elevation of
hearing threshold
at age 5-years
MRI of brain
(hyperintensity on T2/
FLAIR sequences)
Left cerebellar hemisphere, right
cerebellar vermis, left thalamus, left
centrum semiovale
(1) Right and left
frontal lobe, left
thalamus, bilateral
parietal, right occipital
Left cerebellum Semiovale,
cerebellum
periventricular
white matter, right
occipital
(2) Normal
Age of seizure onset (year) 14 15 2.8 9
Seizure type CPS SPS and EPC
myoclonus
CPS, EPC, visual
hallucination, and
myoclonus
CPS, EPC, status
epilepticus
EEG Generalized Right occipital spikes,
normal EEG,
background slow,
PLEDs
Left occipital spikes/
right occipital spikes
(varied with EEG),
background slow
Background slow,
left central and
parietal spikes, left
hemisphere
periodic
discharges,
bilateral occipital
spikes
Drug for seizure control OXC, PHT, VPA LTG stable for 7 years,
VPA
OXC, VPA PHT, CBZ, VPA,
LTG, TOP, CLON
Duration (month) of add-
on VPA before
hepatotoxicity
2 months 3 months 3 months 2.5 months
Course after hepatotoxicity Liver failure, renal failure and
pancreatitis
Liver transplantation,
progressive
encephalopathy
Encephalopathy Psychomotor
regression,
vegetative state
Lactate 30 mmol/L (normal 0.5–1.7 mmol/L) ND Normal Normal
Other phenotype Ophthalmoplegia, peripheral neuropathy Sensorineural hearing
loss, dysmetria,
intention tremor,
hypotonia
Chronic constipation,
cyclic vomiting,
hypotonia, absent
smooth pursuit
Leukodystrophy,
right PCA infarct
in MRI, cortical
blindness at 9.5
years
Outcome Expired at 18.5 years Expired at 23.5 years Expired at 3 years 4
months
Survived
SPS, simple partial seizure; CPS, complex partial seizure; EPC, epilepsia partialis continua; MRI, magnetic resonance imaging; FLAIR, fluid
attenuated inversion recovery; PCA, posterior cerebral artery; CBZ, carbamazepine; PHT, phenytoin; OXC, oxcarbazepine; VPA, valproic acid;
LTG, Lamotrigine; CLON, clonazepam; TOP, topiramate; and PB, phenobarbital; PLEDs, periodic lateralized epileptiform discharges.
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Table 2
Summary of clinical course of patients not exposed to VPA.u.
Patient
5 6
Gender/age (years) Male/11 Female/2
Genotype allele 1/allele 2 c.1399G>A/c.2542G>A c.2542G>A/c.2243G>C
Amino acid change A467T/G848S G848S/W748S
Ethnicity Caucasian Caucasian
Health status before seizure onset Cyclic vomiting, episodic hypoglycemia Normal
MRI of brain (hyperintensity on T2/FLAIR sequences) Normal Normal
Age of seizure onset (years) 6 4
Seizure type Generalized CPS, EPC
EEG Generalized spikes, background slow Right occipital
Drug for seizure control CBZ, OXC, LTG, ZNS, LEV, TPM LEV, OXC
Duration (month) of add-on VPA before hepatotoxicity VPA not given VPA not given
Course after hepatotoxicity N/A N/A
Lactate Normal Normal
Other phenotype GI dysmotility, eyelid ptosis,ophthalmoplegia,
sensorineural hearning loss, absent smooth pursuit
eye movements
Truncal ataxia, intention tremor
Outcome Alive Alive
EEG, encephalogram; MRI, magnetic resonance imaging; FLAIR, fluid attenuated inversion recovery; GI, gastrointestinal; CPS, complex partial
seizure; GTC, general tonic seizure; SE, status epilepticus; VPA, valproic acid; CBZ, carbamazepine; PHT, phenytoin; OXC, oxcarbazepine; LTG,
Lamotrigine; CLON, clonazepam; TPM, topiramate; LEV, levetiracetam; GAB, gabapentin; and FOS, fosphenytoin.
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